907. Outcomes Research: Plasma Cell Disorders: Poster I
0 activities
Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
1 activities
Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
Impact of Protein Energy Malnutrition on Hospitalized Patients with Multiple Myeloma: A United States Population-Based Cohort Study
1 activities
Impact of Protein Energy Malnutrition on Hospitalized Patients with Multiple Myeloma: A United States Population-Based Cohort Study
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
1 activities
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
1 activities
Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
1 activities
Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
1 activities
Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
1 activities
Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
1 activities
Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma
1 activities
The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma
Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
1 activities
Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
1 activities
Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
1 activities
Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
1 activities
Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
1 activities
Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vacc
1 activities
Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes
An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
1 activities
An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
Real Word Autologous Transplant Utilization and Outcomes By Race and Ethnicity
1 activities
Real Word Autologous Transplant Utilization and Outcomes By Race and Ethnicity
Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
1 activities
Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US
1 activities
Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US
Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis
1 activities
Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis
Evaluating Multiple Myeloma Treatment and Clinical-Decision Making with Real-World Data
1 activities
Evaluating Multiple Myeloma Treatment and Clinical-Decision Making with Real-World Data
Assessing the Relationship between Self-Efficacy and Mental Health Amongst Patients Undergoing Hematopoietic Stem Cell Transplant
1 activities
Assessing the Relationship between Self-Efficacy and Mental Health Amongst Patients Undergoing Hematopoietic Stem Cell Transplant
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
1 activities
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Key Drivers for Treatment Choice in Lenalidomide-Exposed and Refractory Multiple Myeloma Patients in the Real World. Analysis Conducted in the EU5 Countries and the US
1 activities
Key Drivers for Treatment Choice in Lenalidomide-Exposed and Refractory Multiple Myeloma Patients in the Real World. Analysis Conducted in the EU5 Countries and the US
Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
1 activities
Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
1 activities
Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
1 activities
Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis
1 activities
Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis
Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2
1 activities
Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2
Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
1 activities
Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
Relationship between Social Deprivation Index, Race and Survival Outcomes Among Multiple Myeloma Patients in a Large, Diverse Population of New York
1 activities
Relationship between Social Deprivation Index, Race and Survival Outcomes Among Multiple Myeloma Patients in a Large, Diverse Population of New York
Racial and Socioeconomic Disparities in Patients with Waldenstroem’s Macroglobulinemia. a SEER Database Analysis
1 activities
Racial and Socioeconomic Disparities in Patients with Waldenstroem’s Macroglobulinemia. a SEER Database Analysis
Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab
1 activities
Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated
Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
1 activities
Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
Functional Decline Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoetic Stem Cell Transplantation
1 activities
Functional Decline Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoetic Stem Cell Transplantation
Disparity in Access to Myeloma CAR-T: A Geospatial Analysis of Distance to CAR-T Centers and Its Impact on Mortality
1 activities
Disparity in Access to Myeloma CAR-T: A Geospatial Analysis of Distance to CAR-T Centers and Its Impact on Mortality